TVM Capital Life Science to participate in LSI USA ’23

MONTREAL and MUNICH, Germany, March 17, 2023 (GLOBE NEWSWIRE) — TVM Capital Life Science (“TVM”), a prime international venture capital firm focused on investments in life sciences innovation, presently announced that Dr. Luc Marengère, Managing Companion, and Dr. Sascha Berger, Standard Companion of TVM, will participate in the upcoming LSI USA ’23 Emerging Medtech Summit 2023, which brings collectively prime innovators, active investors and committed strategics from the medtech industry to companion and generate subsequent-generation healthcare technologies. The conference will take spot March 20-23, 2023, in Dana Point, California, USA.

“Medtech innovation plays a pivotal element in the healthcare ecosystem and has the probable to revolutionize the company by enhancing patient outcomes, increasing efficiency, and decreasing charges. A single unique crucial element of our approach is to invest in disruptive, breakthrough, industrial-stage technologies that map essential future trends and substantially transform present frequent-of-care. In addition to connecting with fellow investors and dealmakers to go more than sector possibilities and demands, we seem forward to meeting young, hugely revolutionary organizations at the LSI Summit to added expand TVM’s robust medtech portfolio,” stated Dr. Luc Marengère.

TVM pursues a distinctive two-pronged approach, investing in differentiated overall health-connected technologies with industrial proof-of-notion and late clinical-stage therapeutics as nicely as financing revolutionary early-stage therapeutics by way of a single asset enterprise strategy (Project-Focused Company, PFC) that leverages TVM’s strategic connection with international pharmaceutical firm, Eli Lilly and Company. With its late-stage medtech investments, the Company focuses on revolutionary organizations from North America or the EU operating to transform overall health-connected practice with their groundbreaking devices and technologies.

Dr. Sascha Berger added: “TVM’s track record of powerful collaboration highlights our partnership and worth-constructing strategy with innovators. As precise partners, we function closely with our portfolio organizations, striving to have an understanding of their ideas, and find out procedures to advance their innovations to accelerate improvement, facilitate sector expansion and sooner or later allow them turn out to be or continue to be a leader in their respective markets. With our present fund TVM Life Science Innovation II, we continue to expand our approach, that has been validated by way of a quantity of organizations in every single Fund I and II, to generate a portfolio of differentiated merchandise with robust leadership teams.”

Investment highlights from TVM’s medtech industrial-stage portfolio consist of:

• Access Vascular Inc. has produced and commercializes award-winning intravenous catheters addressing the most prevalent and pricey complications of intravenous therapy: infection, thrombosis, and phlebitis. Engineered to mimic the body’s all-all-natural chemistry, Access Vascular catheters are produced to evade foreign physique response and linked complications.
• Egg Healthcare has produced and commercializes a lab radiation protection approach that significantly reduces scatter radiation exposure all through interventional angiographic procedures. During an X-ray, radiation reflects off a patient and scatters to anyone else in the space. This final outcomes in an elevated threat of cancer chromosomal abnormalities, skin harm and eye injury for healthcare pros in this field. EGGNEST™ reduces scatter radiation exposure by 91% for the complete group with out interrupting the workflow.
• Emovi’s technologies and AI alternatives address clinical challenges that exist by way of the continuum of care for people with knee discomfort and pathology. The Company has produced the only FDA cleared, Effectively becoming Canada licensed and CE Marked overall health-connected device to assess the 3D motion of the knee and have an understanding of what is taking spot in patient’s knee in order to higher figure out causes of symptoms and propose a powerful care method.
• Kent Imaging, a prime innovator in close to-infrared tissue oxygenation imaging, develops, manufactures, and markets overall health-connected technologies that supports accurate-time decision-creating in wound care, vascular and surgical subspecialties and tracks the healing strategy. Kent Imaging targets limb preservation and reconstructive surgical markets – regions with clear unmet want, as non-healing wounds are a huge burden to people and the healthcare approach.
• Panthera Dental, a globe leader in CAD/CAM implant alternatives and dental sleep appliances, has proficiently combined creativity, science and know-how to bring to sector its proprietary revolutionary technologies to give subsequent-generation merchandise to the dental company as nicely as a novel innovation to treat sleep apnea. The Company just not also extended ago launched a new item: The Magnet-XTM, the world’s initial removable magnetic implant bar giving steady forces, lateral guidance and stability and effortless handling for people with substantially significantly less dexterity.

About TVM Capital Life Science
TVM Capital Life Science (“TVM”) is a prime international venture capital firm focused on investing in life science innovations. The Company has a hugely skilled transatlantic investment group and about $900 million beneath management. TVM’s portfolio focuses on therapeutics and overall health-connected technologies from North America and the EU that represent differentiated initial-in-class or finest-in-class assets with the probable to transform frequent of care.

TVM pursues a distinctive two-pronged approach, financing revolutionary early-stage therapeutics by way of a single asset enterprise strategy (Project-Focused Company, PFC) that leverages the firm’s strategic connection with international pharmaceutical firm, Eli Lilly and Company. TVM also invests in differentiated industrial-stage overall health-connected technologies and late clinical-stage therapeutics.

With its late-stage investments, TVM focuses on differentiated overall health-connected technologies with industrial proof-of-notion as nicely as late-stage therapeutics anticipated to instantly attain huge improvement or regulatory milestones. This approach has been validated by way of a quantity of organizations in every single Fund I and II and the Colucid Pharmaceuticals exit.

The TVM investment group has worked collectively for extra than a decade to proficiently make use of this revolutionary strategy to maximize returns for investors and finance new therapies and technologies to meaningfully boost patient lives.

Media Relations

MC Options AG

Europe: Anne Hennecke
Tel: +49 211 529 252 22
North America: Laurie Doyle
Tel: +1 339 832 0752
E-mail: tvm@mc-options.eu